Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients

Survivin is an inhibitor of apoptosis. Aberrant survivin expression occurs in malignant tumors and has often been linked to unfavorable patient outcome. Here we analyzed 12 432 prostate cancers by immunohistochemistry. Survivin immunostaining was regularly expressed at high levels in normal prostate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Büscheck, Franziska, Sulimankhil, Mariam, Melling, Nathaniel, Höflmayer, Doris, Hube‐Magg, Claudia, Simon, Ronald, Göbel, Cosima, Hinsch, Andrea, Weidemann, Sören, Izbicki, Jacob R., Jacobsen, Frank, Mandelkow, Tim, Blessin, Niclas C., Möller‐Koop, Christina, Lutz, Florian, Viehweger, Florian, Möller, Katharina, Sauter, Guido, Lennartz, Maximillian, Burandt, Eike, Lebok, Patrick, Minner, Sarah, Bonk, Sarah, Huland, Hartwig, Graefen, Markus, Schlomm, Thorsten, Fraune, Christoph
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013067/
https://ncbi.nlm.nih.gov/pubmed/31893572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2773
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados